Compare SFST & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SFST | ARVN |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 578.6M | 516.2M |
| IPO Year | 2012 | 2018 |
| Metric | SFST | ARVN |
|---|---|---|
| Price | $60.76 | $8.35 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 19 |
| Target Price | ★ $64.00 | $15.05 |
| AVG Volume (30 Days) | 145.6K | ★ 724.1K |
| Earning Date | 04-21-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 94.76 | 58.84 |
| EPS | ★ 1.19 | N/A |
| Revenue | $6,282,000.00 | ★ $262,600,000.00 |
| Revenue This Year | $10.47 | N/A |
| Revenue Next Year | $12.19 | N/A |
| P/E Ratio | $51.16 | ★ N/A |
| Revenue Growth | ★ 12.99 | N/A |
| 52 Week Low | $38.48 | $6.06 |
| 52 Week High | $63.75 | $14.22 |
| Indicator | SFST | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 55.39 | 51.52 |
| Support Level | $53.96 | N/A |
| Resistance Level | $61.81 | $10.18 |
| Average True Range (ATR) | 1.68 | 0.41 |
| MACD | -0.08 | 0.12 |
| Stochastic Oscillator | 50.43 | 61.62 |
Southern First Bancshares Inc is a bank holding company. Through its banking subsidiary, it is engaged in the business of accepting demand deposits and savings deposits insured by the Federal Deposit Insurance Corporation (the FDIC), and providing commercial, consumer, and mortgage loans, ATM processing, and other banking products and services to the general public. The group operates through various retail offices located in the Greenville, Columbia, and Charleston markets of South Carolina, three retail offices in the Raleigh, Greensboro, and Charlotte markets of North Carolina, and one retail office in Atlanta, Georgia.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.